Table I.
Human Subjects
| PID | Class | Age | Sex | Race | CD4 | VL (copies/ml) | cART at death | Cog status |
|---|---|---|---|---|---|---|---|---|
| 500 | HIVE | 47 | m | w | 20 | 210000 | none | HIV-D |
| 537 | HIVE | 45 | f | b | 6 | n/a | none | n/a |
| 603 | HIVE | 49 | m | b | 2 | 493381 | none | HIV-D |
| 10017 | HIVE | 44 | m | w | 7 | 389120 | none | npi-o |
| 10070 | HIVE | 37 | m | b | 1 | >750000 | none | ms change |
| 10133 | HIVE | 48 | m | w | 3 | 173921 | d4t, kaletra, nevirapine | MCMD po |
| 540 | HIVE | 47 | m | b | 1 | 683333 | d4t, epivir, sustiva | psychosis |
| 10231 | HIVE | 47 | m | h | 98 | 208516 | tenofovir, epivir, videx, reyataz, norvir | n/a |
| 10016 | HIV+/no E | 58 | f | b | 98 | 576000 | none | MCMD pr |
| 10066 | HIV+/no E | 54 | f | b | 8 | 469163 | none | MCMD po |
| 10011 | HIV+/no E | 44 | m | h | 16 | 162642 | none | MCMD po |
| 10119 | HIV+/no E | 33 | m | b | 1 | 312240 | none | HIV-D po |
| 10203 | HIV+/no E | 44 | f | h | 86 | 36035 | none | npi-o |
| 10067 | HIV+/no E | 28 | m | A | 5 | 2097 | epivir, nelfinavir, effavirenz, tenofovir | MCMD pr |
| 10013 | HIV+/no E | 33 | m | w | 9 | >750000 | videx, abacavir, ritonavir, indinavir | MCMD pr |
| 10001 | HIV+/no E | 64 | f | b | 72 | 359 | d4t, epivir, kaletra | HIV-D po |
| 30024 | HIV+/no E | 43 | m | b | 104 | <50 | epivir, kaletra, hydroxyurea | MCMD po |
| 10127 | HIV+/no E | 39 | f | h | 402 | 1013 | trizivir | npi-o |
| 551 | HIV− | 30 | f | h | - | - | - | n/a |
| 567 | HIV− | 63 | m | h | - | - | - | n/a |
| 588 | HIV− | 21 | m | h | - | - | - | n/a |
| 594 | HIV− | 57 | f | w | - | - | - | n/a |
| 601 | HIV− | 58 | f | h | - | - | - | n/a |
Autopsy frontal white matter (FWM) and basal ganglia (BG) from of 8 HIVE, 10 HIV without encephalitis (HIV+/no E) and 5 seronegative (HIV−) individuals without CNS disease were investigated. All tissues were acquired through the Manhattan HIV Brain Bank (MHBB) NeuroAIDS Tissue Consortium. Neurocognitive diagnoses were assigned by a licensed neuropsychologist of the MHBB. Diagnoses were assigned according to the DANA modification of the American Academy of Neurology (AAN) criteria, which includes to degrees of HIV-related neurocognitive impairment, HIV-associated dementia (HIV-D) and minor cognitive motor disorder (MCMD). The mean age for each grouping are as follows: HIVE = 45.5 years; HIV+/no E = 44 years; HIV− = 45.8 years. “Cog status” refers to the neuropsychological classification diagnosed in life, while “Class” reflects post-mortem CNS findings. Inconsistencies between these two classifications underscores the difficulty in accurately diagnosing these patients. Abbreviations: HIV-D = HIV-associated dementia; MCMD = minor cognitive motor disorder; ms change = mental status change: patient has altered cognitive capacity, however, the individual observing this is unsure if this constitutes dementia or a transient abnormality; pr = probable: no confounds; po = possible: confounds exist, but observer believes cognitive impairment is most likely HIV-associated; npi-o = neuropsychological impairment-other: patient is cognitively impaired and the observer believes there are enough ancillary factors/co-morbid processes to account for the dementia.